RSS-Feed abonnieren
DOI: 10.1055/s-0035-1545924
Stellenwert löslicher rekombinanter Blutgruppenproteine im immunhämatologischen Labor
Rating of Soluble Recombinant Blood Group Proteins in the Immunohematological LaboratoryPublikationsverlauf
Publikationsdatum:
26. Mai 2015 (online)
![](https://www.thieme-connect.de/media/transfusionsmedizin/201502/lookinside/thumbnails/10-1055-s-0035-1545924_tf074-1.jpg)
Zusammenfassung
Seit den 1990er-Jahren sind eine Reihe löslicher rekombinanter Blutgruppenproteine (rBGP) mit einer breiten Palette von klinischen und labortechnischen Einsatzmöglichkeiten entwickelt worden. Das derzeitige rBGP-Portfolio umfasst Substanzen, die auch im klinischen Alltag häufige Erythrozytenalloantikörper mit hoher klinischer Relevanz neutralisieren (z. B. rekombinante Kell-, Duffy-, Lutheran-Blutgruppensystemproteine), und solche, die seltene Alloantikörper unterschiedlicher klinischer Relevanz binden. Von besonderem Interesse sind rBGP, die Antikörper gegen hochfrequente Erythrozytenantigene hemmen. Solche Antikörper sind zwar vergleichsweise selten, decken aber das gesamte Spektrum transfusionsmedizinischer Relevanz (von völliger Asymptomatik bis zu schweren Transfusionsreaktionen und Fällen von Morbus haemolyticus neonatorum, Abk.: MHN) ab und verursachen immer deutlichen Mehraufwand im Labor. Die Daten aus mono- und multizentrischen Studien sowie eigene Untersuchungen zeigen, dass lösliche rBGP ihre Zielantikörper zuverlässig hemmen, während die antithetischen Antikörper im Sinne einer hohen Spezifität nicht neutralisiert werden, und Antikörper gegen andere Blutgruppensysteme unverändert reaktiv bleiben, d. h. in Antikörpergemischen demaskiert und identifiziert werden können. Bei der Differenzierung von Erythrozytenalloantikörpern in Antikörpergemischen und von Antikörpern gegen hochfrequente Erythrozytenantigene machen rBGP die Befundung sicherer und erzielen eine deutliche Beschleunigung der prätransfusionellen Diagnostik.
Abstract
Since the mid-1990s a considerable number of recombinant soluble blood group proteins (rBGP) with a broad range of clinical and laboratory applicability have been developed. The current portfolio of rBGP consists of substances that reliably neutralize frequent red blood cell alloantibodies with high clinical significance encountered in every-day routine (e.g. Kell-, Duffy-, Lutheran red cell antibodies) as well as proteins that bind to rare alloantibodies of different clinical relevance. Of special interest are rBGP that inhibit antibodies to high incidence red cell antigens. These antibodies are relatively rare, but cover the complete range of clinical relevance from symptomlessness to severe transfusion reactions and hemolytic disease of the newborn (HDN) and always cause a significant work load in the immunohematological laboratory. Data from mono- and multicentric studies and from own investigations show that soluble rBGP reliably inhibit their target antibodies while antithetic antibodies remain unaffected suggesting a highly specific binding to the target antibody. Antibodies to other blood group systems in antibody mixtures remain reactive so that they are unmasked and can be more easily recognized by additional antibody testing. In cases of red cell antibody mixtures and in cases of antibodies to high incidence red cell antigens rBGP substantially increase the diagnostic safety and accelerate pretransfusion diagnostic measures.
-
Literatur
- 1 Heuft HG, Genth R, Wittmann G et al. Alloantibodies directed against high-frequency red blood cell antigens. Infusionsther Transfusionsmed 1999; 26: 234-239
- 2 Reid ME. Applications of DNA based systems in blood group antigen and antibody identification. Transfusion 2003; 43: 1748-1757
- 3 Seltsam A, Doescher A. Sequence-based typing of human blood groups. Transfus Med Hemother 2009; 36: 204-212
- 4 Moulds JM, Rowe KE. Neutralization of Knops system antibodies using soluble complement receptor 1. Transfusion 1996; 36: 517-520
- 5 Ridgwell K, Dixey J, Scott ML. Production of soluble recombinant proteins with Kell, Duffy and Lutheran blood group antigen activity, and their use in screening human sera for Kell, Duffy and Lutheran antibodies. Transfus Med 2007; 17: 384-394
- 6 Seltsam A, Grüger D, Blasczyk R. Prokaryotic versus eukaryotic recombinant Lutheran blood group protein for antibody identification. Transfusion 2007; 47: 1630-1636
- 7 Yazdanbakhsh K. Application of blood group antigen expression systems for antibody detection and identification. Transfusion 2007; 47 (Suppl. 01) S85-S88
- 8 Seltsam A, Grueger D, Blasczyk R et al. Easy identification of antibodies to high-prevalence Scianna antigens and detection of admixed alloantibodies using soluble recombinant Scianna protein. Transfusion 2009; 49: 2090-2096
- 9 Seltsam A, Agaylan A, Grueger D et al. Rapid detection of anti-Lu(b) with recombinant Lu(b) protein and the particle gel immunoassay. Transfusion 2008; 48: 731-734
- 10 Seltsam A, Agaylan A, Grueger D et al. Rapid detection of JMH antibodies with recombinant Sema7A (CD108) protein and the particle gel immunoassay. Transfusion 2008; 48: 1151-1155
- 11 Seltsam A, Blasczyk R. Recombinant blood group proteins for use in antibody screening and identification tests. Curr Opin Hematol 2009; 16: 473-479
- 12 Bullock T, Grüger D, Schneeweiß C et al. Evaluation of single and mixed recombinant blood group proteins for detection of antibodies against high-prevalence antigens. Transfus Med Hemother 2012; 39 (S) 21
- 13 Reid ME, Lomas-Francis C. The Blood Group Antigen Facts Book. 2nd. ed. London: Elsevier Academic Press; 2004
- 14 Seltsam A, Wagner F, Lambert M et al. Recombinant blood group proteins facilitate the detection of alloantibodies to high-prevalence antigens and reveal underlying antibodies: results of an international study. Transfusion 2014; 54: 1823-1830
- 15 Heuft HG, Dahm A, Lanz S et al. Soluble recombinant blood group proteins for red blood cell antibody identification. Transfus Med Hemother 2014; 41 (Suppl. 01) 18